Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials

BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety profile and is effective for treatment of plaque psoriasis and psoriatic arthritis. OBJECTIVES: To evaluate the impact of apremilast on health‐related quality of life (HRQOL), general functioning and mental healt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Eur Acad Dermatol Venereol
Main Authors: Thaçi, D., Kimball, A., Foley, P., Poulin, Y., Levi, E., Chen, R., Feldman, S.R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Psoriasis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363239/
https://ncbi.nlm.nih.gov/pubmed/27538241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.13918
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados